Physicians' Academy for Cardiovascular Education

ESC 2019

PACE-CME.org was present at the ESC 2019 in Paris, France. Find coverage of the latest CV news on PACE-CME.

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

10' education - Sep. 12, 2019 - Prof. Alberico Catapano

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

Large community-based studies stress the impact of preventive measures

3' education - Sep. 9, 2019 - Prof. Salim Yusuf

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Prof. François Mach

Importance of continuous use of secondary prevention therapy after CABG

3' education - Sep. 3, 2019 - Erik Björklund

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens

All-cause mortality benefit with ICD use in STEMI patients treated with primary PCI

3' education - Sep. 3, 2019 - Danielle Haanschoten

Primary PCI is the best strategy for STEMI patients compared to fibrinolysis

3' education - Sep. 2, 2019 - Michael Maeng, MD

Clear results with NOAC monotherapy in patients with CAD and AF

3' education - Sep. 2, 2019 - Prof. Freek Verheugt

10-year outcomes with CABG versus PCI in patients with three-vessel disease or left main CAD

3' education - Sep. 2, 2019 - Daniel Thuijs

Early and sustained vasodilation strategy fails to improve outcomes in acute HF

3' education - Sep. 2, 2019 - Prof. Christian Müller

Community-wide salt restriction reduces blood pressure and incidence of hypertension

3' education - Sep. 2, 2019 - Prof. Jaime Miranda

DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI

3' education - Sep. 1, 2019 - Prof. Deepak Bhatt

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France

Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results

3' education - Sep. 1, 2019 - Prof. Stefanie Schüpke

Major benefits with implementation of rapid rule-out pathway for MI

3' education - Sep. 1, 2019 - Prof. Nicholas Mills

ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint

3' education - Sep. 1, 2019 - Prof. Scott Solomon

The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society

10' education - Sep. 12, 2019 - Prof. Alberico Catapano
Prof. Alberico Catapano (Past President EAS) highlights the most important changes in risk classification and treatment goals for LDL-c according to total CV risk in the new 2019 ESC/EAS Dyslipidemia Guidelines.

ESC 2019 Prof. Alberico Catapano (Past President EAS) highlights the most important changes in risk classification and treatment goals for LDL-c according to total CV risk in the new 2019 ESC/EAS Dyslipidemia Guidelines.

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg
The THEMIS study evaluated the effect of ticagrelor vs. placebo on top of aspirin in diabetes patients with stable coronary artery disease. Netto clinical benefit depended on having a history of PCI or not.

ESC 2019 The THEMIS study evaluated the effect of ticagrelor vs. placebo on top of aspirin in diabetes patients with stable coronary artery disease. Netto clinical benefit depended on having a history of PCI or not.

Large community-based studies stress the impact of preventive measures

3' education - Sep. 9, 2019 - Prof. Salim Yusuf
Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.

ESC 2019 Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.

FH patients insufficiently treated, reveals global FH registry

News - Sep. 9, 2019

The first data in the FH Studies Collaboration registry show that among 42,000 adults with heterozygous FH, about half of patients received a statin and the majority was not at LDL-c goal.

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Prof. François Mach
Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.

ESC 2019 Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.

Five updated ESC Guidelines presented during this year’s congress

News - Sep. 8, 2019

ESC 2019 Brief impression of the new ESC recommendations on acute pulmonary embolism, supraventricular tachycardia and chronic coronary syndromes.

Importance of continuous use of secondary prevention therapy after CABG

3' education - Sep. 3, 2019 - Erik Björklund
Erik Björklund summarizes findings from long-term data of the SWEDEHEART registry on use of secondary prevention therapies and association with mortality.

ESC 2019 Erik Björklund summarizes findings from long-term data of the SWEDEHEART registry on use of secondary prevention therapies and association with mortality.

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew
Compared to a three-hour protocol, a one-hour hs-troponin protocol reduced length of stay and was safe up to 30 days for patients with suspected ACS.

ESC 2019 Compared to a three-hour protocol, a one-hour hs-troponin protocol reduced length of stay and was safe up to 30 days for patients with suspected ACS.

Genotype-guided strategy to select oral P2Y12 inhibitor in STEMI lowers bleeding risk

News - Sep. 3, 2019
Selection of an oral P2Y12 inhibitor based on a genetic test for a loss-of-function allele that makes people non-responsive to clopidogrel did not increase stent thrombosis and reduced bleeding events.

ESC 2019 Selection of an oral P2Y12 inhibitor based on a genetic test for a loss-of-function allele that makes people non-responsive to clopidogrel did not increase stent thrombosis and reduced bleeding events.

Secondary prevention therapy use after CABG declines over time

News - Sep. 3, 2019
Data from SWEDEHEART show that use of statins, RAAS-inhibitors and platelet inhibitors is associated with a significant reduction in mortality risk, while beta-blockers were not.

ESC 2019 Data from SWEDEHEART show that use of statins, RAAS-inhibitors and platelet inhibitors is associated with a significant reduction in mortality risk, while beta-blockers were not.

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens
Implementation of a genotype-guided strategy for the selection of clopidogrel or more potent P2Y12 inhibitors was as good as standard treatment for net clinical benefit and reduced bleeding.

ESC 2019 Implementation of a genotype-guided strategy for the selection of clopidogrel or more potent P2Y12 inhibitors was as good as standard treatment for net clinical benefit and reduced bleeding.

New ESC/EASD Guidelines on diabetes no longer regard metformin as first-line therapy

News - Sep. 3, 2019
As a consequence of recent outcome trials of new therapies for diabetes, new treatment recommendations now include use of SGLT2 inhibitors and GLP-1RA.

ESC 2019 As a consequence of recent outcome trials of new therapies for diabetes, new treatment recommendations now include use of SGLT2 inhibitors and GLP-1RA.

ESC 2019
ESC 2019
ESC 2019